Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2006, vol. 15, nr 4, July-August, p. 625–630

Publication type: original article

Language: English

A Proline−Rich Polypeptide Complex – Its Influence on Cytokine Induction in the Blood of Alzheimer’s Patients

Kompleks polipeptydowy bogaty w prolinę – wpływ na indukcję cytokin we krwi chorych na chorobę Alzheimera

Jerzy Leszek1,, Agnieszka Zabłocka2,, Józefa Macała2,, Elżbieta Trypka1,, Maria Janusz2,

1 Department and Clinic of Psychiatry, Silesian Piasts University of Medicine in Wrocław, Poland

2 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

Abstract

Background. The function of cytokines in neurodegenerative disorders has become a topic of intensive investigation. A proline−rich polypeptide complex (PRP) with immunomodulatory properties and psychotropic activity is a modest cytokine inducer. In the form of orally administered tablets it improves outcome in Alzheimer’s patients.
Objectives. To further explore the role of PRP, the release of IL−1β, IL−6, IL−10, and TNF−α in cultured AD patient whole−blood samples was investigated. Control samples were collected from healthy persons of similar age.
Material and Methods. Blood samples taken from 20 AD patients (10 women and 10 men, mean age: 70 ± 7.9 years) and 10 healthy controls (6 women and 4 men, mean age: 68 ± 6.2 years) were investigated. LPS + PHA was used for cytokine induction. The interleukins were determined by microplate ELISA.
Results. In the absence of inducers, no statistically significant differences were found in the plasma of the controls and AD patients. In the presence of standard inducers (LPS + PHA) as well as in the presence of PRP (1–100 μg), secretion of IL−1β, IL−6, IL−10, and TNF−α was induced in both the control and AD blood samples. The level of induced cytokines increased with disease progression. Some modulatory effect of PRP added to the blood cell cultures simultaneously with or after LP induction was observed in the cases of IL−6 and IL−10.
Conclusion. The results presented here could shed some light on explaining the therapeutic effect of PRP in Alzheimer’s disease.

Streszczenie

Wprowadzenie. Cytokiny odgrywają ważną rolę w procesach neurodegeneracyjnych ośrodkowego układu nerwowego. Kompleks polipeptydowy bogaty w prolinę (PRP) o właściwościach immunomodulatorowych i psychotropowych jest induktorem wydzielania cytokin. Podawany pacjentom w postaci tabletek miał korzystne rezultaty terapeutyczne w przypadku choroby Alzheimera.
Cel pracy. W celu wyjaśnienia niektórych aspektów działania PRP określono wpływ na uwalnianie IL−1β, IL−6, IL−10 i TNF−α w hodowlach komórek pełnej krwi chorych. Kontrolę stanowiły próbki krwi pobrane od zbliżonej wiekiem grupy osób zdrowych.
Materiał i metody. Badaniami objęto 20 osób chorych z lekkim i średnim zaawansowaniem choroby (10 kobiet i 10 mężczyzn, średni wiek 70 ± 7.9 lat). Grupę kontrolną stanowiło 10 osób (6 kobiet i 4 mężczyzn w wieku 68 ± ± 6.2 lat). Stężenie cytokin oznaczano za pomocą handlowo dostępnych testów ELISA.
Wyniki. Przy braku czynników indukujących nie stwierdzono istotnych różnic w stężeniu badanych cytokin w osoczu chorych w odniesieniu do grupy kontrolnej. Pod wpływem induktorów LPS + PHA oraz PRPw dawkach 1–100 μg zarówno w krwi kontrolnej, jak i chorych indukowane jest wydzielanie IL−1β, IL−6, IL−10 i TNF−α. Ilość wydzielanych cytokin wzrasta wraz z progresją choroby. Pewien modulatorowy efekt PRP obserwowano w przypadku IL−6 i IL−10.
Wnioski. Uzyskane wyniki pozwalają tylko częściowo określić rolę PRP w regulacji wydzielania cytokin. Niemniej można sądzić, że PRP przez indukcję i modyfikację wydzielania cytokin może regulować procesy zachodzące w obrębie układu nerwowego.

Key words

Alzheimer’s disease, whole−blood samples, cytokine induction, PRP

Słowa kluczowe

choroba Alzheimera, hodowle komórek pełnej krwi, stężenie cytokin, PRP

References (20)

  1. Giulian D: Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet 1999, 65, 13–18.
  2. Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, DeLuca G, Salvatore M, Conti P, Gambi D: Treatment with acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro−inflammatory and anti−inflammatory cytokines. J Neuroimmunol 2004, 148, 162–171.
  3. Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D: Acetylcholinesterase inhibitors effects on oncostatin−M, interleukin−1β and interleukin−6 release from lymphocytes of Alzheimer’s disease patients. Exp Gerontol 2005, 40, 165–171.
  4. Shepherd AJ, Downing JEG, Miyan JA: Without nerves, immunology remains incomplete – in vivo veritas. Immunology 2005, 116, 145–163.
  5. Janusz M, Starościk K, Zimecki M, Wieczorek Z, Lisowski J: Chemical and physical characterization of a proline−rich polypeptide from sheep colostrum. Biochem J 1981, 199, 9–15.
  6. Janusz M, Lisowski J: Proline−rich polypeptide (PRP) – an immunomodulatory peptide from ovine colostrum. Arch Immunol Ther Exp 1993, 41, 275–279.
  7. Inglot AD, Janusz M, Lisowski J: Colostrinine: a proline−rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes. Arch Immunol Ther Exp 1996, 44, 215–224.
  8. Zabłocka A, Janusz M, Rybka K, Wirkus−Romanowska I, Kupryszewski G, Lisowski J: Cytokine−inducing activity of a proline−rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs. Eur Cytokine Netw 2001, 12, 462–467.
  9. Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA: Colostrinin®: a proline−rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer’s disease. A double−blind, placebo−controlled study. Arch Immunol Ther Exp 1999, 47, 377–385.
  10. Bilikiewicz A, Gaus W: Colostrinin (a naturally occurring, proline−rich, polypeptide mixture) in the treatment of Alzheimer’s disease. J Alzheimer’s Dis 2004, 6, 17–26.
  11. Tanga FY, Nutile−McMenemy N, DeLeo JA: The CNS role of Toll−like receptor 4 in innate neuroimmunity and painful neuropathy. PNAS 2005, 102, 5856–5861.
  12. Zabłocka A, Janusz M, Rybka K, Wirkus−Romanowska I, Miecznikowska H, Kupryszewski G, Lisowski J: Aproline−rich polypeptide complex and analogues of its active nonapeptide affect induction of cytokines and reactive oxygen species. Immunol Lett 2000, 73, 223.
  13. Boldogh J, Hughes TK, Georgiades JA, Stanton J: Antioxidant effect of Colostrinin and its component peptides. Yearb Psychogeriatr 2001, 4, 57–65.
  14. Boldogh I, Liebenthal D, Hughes TK, Juelich TL, Georgiades JA, Kruzel ML, Stanton GJ: Modulation of 4HNE−mediated signaling by proline−rich peptides from ovine colostrum. J Mol Neurosci 2003, 20, 125–134.
  15. Stanton JS, Boldogh IS, Georgiades JA, Hughes TK: Induction of proliferation and cytokines by Colostrinin® and component proline−rich peptides in human peripheral blood leukocytes. Yearb Psychogeriatr 2001, 4, 67–75.
  16. Alvarez XA, Franco A, Fernandez−Novoa A, Cacabelos R: Blood levels of histamine, IL−1beta and TNF−alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 1996, 29, 237–252.
  17. Bonaccorso S, Lin A, Song C, Verkerk R, Kenis G, Bosmans E, Scharpe S, Vanderwoude M, Dossche A, Maes M: Serotonine−immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin−6 in DAT. Aging (Milano) 1998, 10, 316–323.
  18. Licastro G, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LME: Increased plasma levels of interleukin−1, interleukin−6 and α−1−antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000, 103, 97–102.
  19. Angelis P, Sharf S, Mander A, Vajda F, Christophidis N: Serum interleukin−6 and interleukin−6 soluble receptors in Alzheimer’s disease. Neurosci Lett 1998, 244, 106–108.
  20. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella M.A, Rossi F: Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with β−amyloid [25−35]. J Neuroimmunol 1999, 93, 45–52.
© Wroclaw Medical University